Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
How did BPTSY's recent EPS compare to expectations?
The most recent EPS for Biophytis S.A. is $, expectations of $.
How did Biophytis S.A. BPTSY's revenue perform in the last quarter?
Biophytis S.A. revenue for the last quarter is $
What is the revenue estimate for Biophytis S.A.?
According to of Wall street analyst, the revenue estimate of Biophytis S.A. range from $ to $
What's the earning quality score for Biophytis S.A.?
Biophytis S.A. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Biophytis S.A. report earnings?
Biophytis S.A. next earnings report is expected in 2025-11-11
What are Biophytis S.A.'s expected earnings?
Biophytis S.A. expected earnings is $, according to wall-street analysts.